/	OIPE
	MON 5 5 5000
	TRADEMARKS TRADEMARKS

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO			Complete If Known		
Subsitu	te 10/10/11/14-3/- 10		•	Application Number	10/620,404	
INF	ORMATION	N DIS	CLOSURE	Filing Date	07/16/2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	James M. Ntambi	
				Art Unit.	1614	
	· (Use as many sh	ieets as i	iecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	960296,99128	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
NWS		Enser, M., "Desaturation of Stearic Acid by Liver and Adipose Tissue from Obese-Hyperglycaemic Mice (ob/ob)," Biochem. J. 148:551-555 (1975)				
		Jones, B.H., et al., "Adipose tissue stearoyl-CoA desaturase mRNA is increased by obesity and decreased," Am. J. Physiol. Edocrinol. Metab. 271:E44-E49 (1996)				
		Singh, M.V., et al., "Nuclear factor 1 is essential for the expression of stearoyl-CoA desaturase 1 gene," Biochim. Biophys. Acta. 1398:148-156 (1998)				
V		Storlien, L.H., et al, "Influence of Dietary Fat Compositions on Development of Insulin 'Resistance in Rats. Relationship to Muscle Triglyceride," Diabetes 40:280-289 (1991)				
NWS		Waters, K.M., et al., "Polyunsaturated Fatty Acids Inhibit Hepatic Stearoyl-CoA Desaturase-1 Gene in Diabetic Mice," Lipids 31:S33-S36 (1996)				
		*				
•						

	<u> </u>			
ı	Examiner	/27. bl 0-12.1b-/	Date	11/21/2006
ı	Signature	/Nathan Schlientz/	Considered	11/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

and The	
OIPE	
NOV 1 2 2004 를	
& TRADE LInde	

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/620,404 Filing Date 07/16/2003 INFORMATION DISCLOSURE First Named Inventor James M. Ntambi STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number 960296.99128 Sheet 1

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (4 known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NWS		^{US-} 4,910,224	03/20/1990	Habib et al.	
NWS		^{US-} 2003/0064950 A1	04/03/2003	Ntambi et al.	
NWS		^{US-} 2003/0157552 A1	08/21/2003	Hayden et al.	
		US-			
-		US-			
		US-		·	
		US-			
		US→			
		US-			

			IGN PATENT DOCL		T 5	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Ľ
NWS		WO 01/62954 A2	08/30/2001	Xenon Genetics, Inc. et al.	(excerpts and all	
					claims as published)	
						L
						L
						L
						ı

Examiner Signature	/Nathan Schlientz/	Date Considered	11/21/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known
Substitu	ite for form 1449/PTC	,		Application Number	10/620,404
INF	ORMATIO	N DIS	CLOSURE	Filing Date	07/16/2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	James M. Ntambi
				Art Unit	1614
	(Use as many s	theets as n	ecessary)	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	960296.99128

	_	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NWS		BALL, CA, et al., "Standards for Microarray Data," Science 298:539-542 (2002)	
		COHEN, P, et al., "Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss," Science 297:240-243 (2002)	
		KAKUMA, T, et al., "Effects of leptin, troglitazone, and dietary fat on stearoyl CoA desaturase," Biochemical and Biophysical Research Commun. 297:1259-1263 (2002)	
		KUREBAYASHI, S, et al., "Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gen expression in 3T3-L1 adipocytes," Diabetes 46:2115-2118 (1997) Abstract	
		MIYAZAKI, M, et al., "The Biosynthesis of Hepatic Cholesterol Esters and Triglycerides Is Impaired in Mice," The Journal of Biological Chemistry 275:30132-30138 (2000)	
		MIYAZAKI, M, et al., "A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene," Journal of Lipid Research 42:1018-1024 (2001)	
		MIYAZAKI, M, et al., "Targeted Disruption of Stearoyl-CoA Desaturase 1 Gene in Mice Causes Atrophy of Sebaceous," J. Nut. 131:2260-2268 (2001)	
		NTAMBI, JM, "Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol," Journal of Lipid Research 40:1549-1558 (1999)	
$\sqrt{}$		NTAMBI, JM, et al., "Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity," PHAS 99:11482-11486 (2002)	
NWS		SESSLER, AM, et al., "Regulation of Stearoyl-CoA Desaturase 1 mRNA Stability by Polyunsaturated Fatty Acids," Journal of Biological Chemistry 271:29854-29858 (1996)	

Examiner Date Considered 11/21/2006	·	
---	---	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, where or not clasion is in conformance with MPEP 695. Draw line through clastic into the considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substit	ute for form 1449B/PTC	,		Co	implete if Known
				Application Number	10/620,404
INF	ORMATION	1 C	ISCLOSURE	Filing Date	07/16/2003
STA	TEMENT P	3 Y	APPLICANT	First Named Inventor	James M. Ntambi
017	· · · · · · · ·	•	All LIOAN	Group Art Unit	1614
	(use as many s	heet	s as necessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	960296.99128

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
NWS		UNGER, RH, "Lipotoxic Diseases," Annu. Rev. Med. 53:319-336 (2002)				
		•				
•						

(Fuenisse		Date	
Examiner Signature	/Nathan Schlientz/	Considered	11/21/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.